Results 151 to 160 of about 73,182 (252)

Programmable Immunotherapy in Solid Tumors: MRNA‐Based Nanobody Platforms to Overcome Barriers to CAR‐T Therapy

open access: yesAdvanced Oncology, Volume 1, Issue 1, December 2026.
Programmable mRNA‐nanobody platforms integrate compact VHH‐based targeting, transient mRNA expression, and adaptable CAR engineering to address major barriers to CAR‐T therapy in solid tumors. Their modular design enables flexible antigen recognition, controllable therapeutic activity, and potential adaptation to tumor evolution, providing an emerging ...
Li Ma   +12 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications

open access: yesMedComm, Volume 7, Issue 12, December 2026.
1. This paper proposes the “oncobiome” as a unifying conceptual framework that integrates commensal, pathobiont, and tumor‐resident microbes into a coherent biological processor driving malignancy. 2. This study describes the dynamic shift from a homeostatic microbiome to a pathological oncobiome, detailing how diet, antibiotics, and environment ...
Xuan Zhang   +6 more
wiley   +1 more source

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment. [PDF]

open access: yesJ Hematol Oncol
Li Y   +13 more
europepmc   +1 more source

Integrative Bioinformatics‐Driven Discovery of the Novel Chimeric Antigen Receptor (CAR)‐T Cell Targets Erb‐B2 Receptor Tyrosine Kinase 3 (ErbB3) and Solute Carrier Family 1 Member 5 (SLC1A5) in Melanoma

open access: yesMedComm, Volume 7, Issue 12, December 2026.
Integrative bioinformatics‐driven discovery of novel chimeric antigen receptor (CAR)‐T cell targets in melanoma. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy has shown limited success in solid tumors, mainly because of the scarcity of tumor‐specific surface antigens.
Kilian F. Juraschek   +12 more
wiley   +1 more source

The role and function of CTLA-4 in Sjögren's syndrome. [PDF]

open access: yesFront Immunol
Wen J, Zhang L, Xie L, Zhou D, Chen M.
europepmc   +1 more source

Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 4, Page 859-875, December 2026.
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta   +2 more
wiley   +1 more source

Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors. [PDF]

open access: yesESMO Gastrointest Oncol
Alsina M   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy